Pulmocide

Pulmocide is a clinical-stage biotech advancing inhaled therapies for severe respiratory fungal infections. Its lead asset, opelconazole, is a potent inhaled antifungal in a pivotal Phase 3 trial for invasive pulmonary aspergillosis in patients failing standard care, supported by FDA Fast Track and QIDP designations. The company leverages a specialized team with deep expertise in inhaled drug discovery and development. Backed by top-tier investors, Pulmocide is positioned to address a significant unmet need in a high-mortality disease area with a targeted therapeutic approach.

Discovery and development of inhaled small-molecule therapies designed for localized delivery to the lung, aiming for high drug concentration at the site of disease with minimal systemic exposure.

Opelconazole competes in the antifungal market against established systemic azoles (e.g., voriconazole, isavuconazole), echinocandins, and amphotericin B formulations. Its primary differentiation is the inhaled, localized delivery route. Competition also comes from other companies developing novel antifungals, though few are focused on inhaled delivery for IPA.